Skip to main content

Eupraxia Pharmaceuticals Inc(EPRX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low6.98
Day High7.88
Open:7.41
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis 
Tipranks
Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences
GlobeNewswire
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
Tipranks
Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Cantor Fitzgerald
Tipranks
Eupraxia Pharmaceuticals (EPRX) Receives a Rating Update from a Top Analyst
Tipranks
Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances
GlobeNewswire
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Tipranks
Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing
Tipranks
Cantor Fitzgerald Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
GlobeNewswire
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Tipranks
Eupraxia Pharmaceuticals Raises US$63.2 Million in February 2026 Equity Offering to Advance GI Pipeline
Tipranks
Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Cantor Fitzgerald
Tipranks
Eupraxia Pharmaceuticals (EPRX) Gets a Buy from Bloom Burton
Tipranks
Eupraxia Pharmaceuticals Raises US$63.2 Million to Advance GI Pipeline and Commercial Readiness
Tipranks
Eupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact
GlobeNewswire
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Tipranks
Eupraxia Raises US$55 Million to Accelerate EP-104GI and GI Pipeline
Tipranks
Eupraxia Pharmaceuticals Plans Public Offering to Fund GI Drug Pipeline
GlobeNewswire
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
GlobeNewswire
Eupraxia Pharmaceuticals Announces Proposed Public Offering
Tipranks
H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
GlobeNewswire
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy 
Tipranks
Cantor Fitzgerald Reaffirms Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
Tipranks
Eupraxia Pharmaceuticals Reports Promising 52-Week Data for EoE Treatment
GlobeNewswire
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI
Tipranks
Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results
GlobeNewswire
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
Tipranks
Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion
Tipranks
Craig-Hallum Remains a Buy on Eupraxia Pharmaceuticals (EPRX)
Tipranks
Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)
Tipranks
Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering
GlobeNewswire
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

Profile

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.